Benzodiazepine Dimer ADCs for Targeted DNA Cross-Linking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Benzodiazepine derivatives used as antitumor agents are highly toxic at low doses, necessitating the development of compounds with lower toxicity while maintaining therapeutic efficacy and a high therapeutic window.
Innovation Solution
Development of cytotoxic benzodiazepine dimer derivatives with chloromethyl and imine functional groups, which form ternary ring structures for enhanced DNA cross-linking, incorporated into antibody-drug conjugates for targeted tumor therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If benzodiazepine derivatives are used as antitumor agents, then anti-tumor activity is achieved, but toxicity increases at low doses
Solution Approach 1:
The patent applies segmentation by dividing the benzodiazepine structure into a dimer configuration where two benzodiazepine units are linked together. This segmentation transforms the monomeric structure into a dimeric structure that reduces toxicity while maintaining anti-tumor activity. The dimer structure allows for controlled drug release and reduced off-target effects compared to monomeric benzodiazepines.
Solution Approach 2:
The patent employs composite materials by combining benzodiazepine units with linker molecules to form a dimer compound. The composite structure integrates multiple functional elements: the cytotoxic benzodiazepine moieties and the connecting linker, creating a new molecular entity with improved therapeutic properties. This composite approach enables the drug to achieve both efficacy and safety by distributing the toxic functional groups in a controlled manner.
2Reliability
If benzodiazepine derivatives are used to achieve therapeutic effect, then anti-tumor efficacy is improved, but therapeutic window narrows due to high toxicity
Solution Approach 1:
The dimer structure segments the cytotoxic functionality into two separate benzodiazepine units connected by a linker, which allows the drug to maintain potent anti-tumor activity while reducing the concentration required for therapeutic effect. This segmentation contributes to a broader therapeutic window by decoupling efficacy from toxicity.
Solution Approach 2:
The patent applies parameter changes by modifying the molecular structure from monomeric to dimeric benzodiazepine, which fundamentally alters the pharmacokinetic and pharmacodynamic parameters. The dimer structure changes the drug's stability, release profile, and interaction with DNA, thereby expanding the therapeutic window while maintaining efficacy.
3Reliability
If chloromethyl and imine functional groups are added to enhance DNA cross-linking, then anti-tumor activity increases, but molecular complexity increases
Solution Approach 1:
The patent applies merging by combining two benzodiazepine units with chloromethyl and imine functional groups into a single dimer molecule. This merging of multiple functional elements into one integrated structure achieves enhanced DNA cross-linking capability while managing molecular complexity through systematic molecular design. The functional groups are strategically positioned to maximize cross-linking efficiency.
Solution Approach 2:
The dimer compound represents a composite molecular structure that integrates multiple functional components: benzodiazepine rings, chloromethyl groups, imine linkages, and connector moieties. This composite molecular architecture achieves complex biological functionality (DNA cross-linking) through the coordinated action of its constituent elements, thereby managing overall molecular complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The benzodiazepine dimer derivatives exhibit improved safety and efficient anti-tumor activity with a broader therapeutic window, offering a more effective and less toxic treatment option for various cancers.
Implementation Method 1
react with guanine in the minor groove of DNA to form DNA adducts, interfering with the processing of DNA
Implementation Method 2
chloromethyl is a precursor drug structure that enters the body to form a ternary ring structure
Implementation Method 3
ADCs utilize the specific recognition of an antigen by an antibody to transport the drug molecules to the vicinity of the target cell
Data Source
AI summary
A DNA toxic dimer compound and its conjugate or a pharmaceutically acceptable salt thereof, method of making and methods of using the compounds or conjugates in preventing or treating cancer. The conjugate may specifically bind to receptors highly expressed in tumor cells. It has good water solubility, stability, and homogeneity, and may be used to prevent or treat tumors or other diseases.